Who are Oncopatch's investors?

Oncopatch's investors include FirstMile Ventures, MINES VENTURE.

How much funding has Oncopatch raised?

Oncopatch has disclosed $418.8K raised across 1 round.

Where is Oncopatch headquartered?

Oncopatch is headquartered in Boulder, US.

Oncopatch

Boulder, US · Founded 2023 · Delaware corporation · 2 known investors

OncoPatch develops a non-invasive medical patch that delivers low-energy beta therapy to treat non-melanoma skin cancers, including basal and squamous cell carcinomas. The single-application treatment is administered in a physician's office and targets cancer cells while sparing healthy tissue.

Biotech Medical Devices

Founders & leadership

Oncopatch was founded in 2023 by David Westerly, Quentin Diot, Frederic Sarazin, and Jeramy Zimmerman.

David WesterlyCo-founder & CEO

Quentin DiotCo-founder

Frederic SarazinCo-founder

Jeramy ZimmermanCo-founder

Board

Bill Miller in 𝕏Board directorFounder / Managing Partner at FirstMile Ventures

Investors · 2

FirstMile VenturesDenver · $300K – $800K

MINES VENTUREGolden

Reported raises · per SEC filings

Form D private placements

$418.8K disclosed across 1 round · 2025

▶$418.8KraisedDec 2025 · 5 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Quentin DiotExecutive Officer, Promoter
Frederic SarazinExecutive Officer, Director, Promoter
David Clark WesterlyExecutive Officer, Director, Promoter
Bill MillerDirector
Jeramy ZimmermanExecutive Officer, Promoter

Offering amount: $2M
Amount sold: $418.8K
First sale: Oct 2025
Incorporated: Corporation, Delaware, 2023
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Oncosenx3 shared keywordsOncoSenX is a late-stage pre-clinical cancer therapeutics company developing treatments that target solid tumors based on transcriptional activity. Its system pairs a patented Proteo-Lipid Vehicle (PLV) delivery agent with plasmid DNA payloads that induce apoptosis in cancer cells while sparing adjacent cells.

Companies competing with Oncopatch for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Oncopatch do?: OncoPatch develops a non-invasive medical patch that delivers low-energy beta therapy to treat non-melanoma skin cancers, including basal and squamous cell carcinomas. The single-application treatment is administered in a physician's office and targets cancer cells while sparing healthy tissue.
Who founded Oncopatch?: Oncopatch was founded by David Westerly, Quentin Diot, Frederic Sarazin, Jeramy Zimmerman in 2023.
Who are Oncopatch's investors?: Oncopatch's investors include FirstMile Ventures, MINES VENTURE.
How much funding has Oncopatch raised?: Oncopatch has disclosed $418.8K raised across 1 round.
Where is Oncopatch headquartered?: Oncopatch is headquartered in Boulder, US.